重症肝病并发侵袭性真菌病的诊治

臧红; 辛绍杰

doi:10.3969/j.issn.1001-5256.2016.09.012

重症肝病并发侵袭性真菌病的诊治

DOI: 10.3969/j.issn.1001-5256.2016.09.012

臧红,
辛绍杰

1. 解放军第三○二医院肝胆外科中心移植内科
2. 解放军第三○二医院肝衰竭诊疗与研究中心

详细信息

中图分类号: R575;R519
计量
- 文章访问数: 2363
- HTML全文浏览量: 40
- PDF下载量: 519
- 被引次数: 0
出版历程
- 出版日期: 2016-09-20

Diagnosis and treatment of invasive fungal diseases in patients with severe liver diseases

Liver Disease Diagnosis and Treatment Center, 302 Hospital of PLA

摘要

摘要:
重症肝病并发侵袭性真菌病(IFD)是影响重症肝病患者预后的重要因素,其早期诊断仍是困扰临床医生的重要问题。临床最常见的4种IFDs是念珠菌病、曲菌病、隐球菌病以及肺孢子菌肺炎,在重症肝病患者临床诊疗过程中重视并发IFD的可能,尤其对存在高危因素的患者,及早发现、及时诊断、恰当治疗,对改善危重症肝病的预后至关重要。
- 肝疾病 /
- 真菌病 /
- 诊断 /
- 治疗
Abstract:
Invasive fungal diseases( IFDs) are an important factor affecting the prognosis of patients with severe liver diseases,and their early diagnosis remains a challenge for clinicians. The four most commonly seen IFDs are candidiasis,aspergillosis,cryptococcosis,and pneumocystis pneumonia. We should pay attention to the risk of developing IFDs in patients with severe liver diseases during clinical management. Particularly,early diagnosis and proper treatment of IFDs are important in high- risk patients. These are vital to improving the prognosis of patients with severe liver diseases.
- liver diseases /
- mycoses /
- diagnosis /
- therapy

HTML全文

参考文献(46)

[1]HASSAN EA,EL-REHIM AS,HASSANY SM,et al.Fungal infection in patients with end-stage liver disease:low frequency or low index of suspicion[J].Int J Infect Dis,2014,23:69-74.

[2]THEOCHARIDOU E,AGARWAL B,JEFFREY G,et al.Early invasive fungal infections and colonization in patients with cirrhosis admitted to the intensive care unit[J].Clin Microbiol Infect,2016,22(2):189.e1-e7.

[3]SCHMIEDEL Y,ZIMMERLI S.Common invasive fungal diseases:an overview of invasive candidiasis,aspergillosis,cryptococcosis,and Pneumocystis pneumonia[J].Swiss Med Wkly,2016,146:w14281.

[4]MABEE CL,MABEE SW,KIRKPATRICK RB,et al.Cirrhosis:a risk factor for cryptococcal peritonitis[J].Am J Gastroenterol,1995,90(11):2042-2045.

[5]BROWN GD,DENNING DW,GOW NA,et al.Hidden killers:human fungal infections[J].Sci Transl Med,2012,4(165):165rv13.

[6]MEAN M,MARCHETTI O,CALANDRA T.Bench-to-bedside review:Candida infections in the intensive care unit[J].Crit Care,2008,12(1):204.

[7]YAPAR N.Epidemiology and risk factors for invasive candidiasis[J].Ther Clin Risk Manag,2014,10:95-105.

[8]ANAISSIE EJ,STRATTON SL,DIGNANI MC,et al.Pathogenic Aspergillus species recovered from a hospital water system:a 3-year prospective study[J].Clin Infect Dis,2002,34(6):780-789.

[9]CHEN LY,KUO SC,WU HS,et al.Associated clinical characteristics of patients with candidemia among different Candida species[J].J Microbiol Immunol Infect,2013,46(6):463-468.

[10]ALASTRUEY-IZQUIERDO A,MELLADO E,PELAEZ T,et al.Population-based survey of filamentous fungi and antifungal resistance in Spain(FILPOP Study)[J].Antimicrob Agents Chemother,2013,57(7):3380-3387.

[11]RAMANA K,KANDI S,BHARATKUMAR P,et al.Invasive fungal infections:a comprehensive review[J].Am J Infect Dis Microbiol,2013,1(4):64-69.

[12]GUSTOT T,MAILLART E,BOCCI M,et al.Invasive aspergillosis in patients with severe alcoholic hepatitis[J].J Hepatol,2014,60(2):267-274.

[13]WU Z,LING Z,SHAO F,et al.Invasive pulmonary aspergillosis in patients with acute-on-chronic liver failure[J].J Int Med Res,2012,40(5):1958-1965.

[14]KHALID A,CLOUGH LA,SYMONS RC,et al.Incidence and clinical predictors of ocular candidiasis in patients with Candida fungemia[J].Interdiscip Perspect Infect Dis,2014,2014:650235.

[15]CLANCY CJ,NGUYEN MH.Finding the“missing 50%”of invasive candidiasis:how nonculture diagnostics will improve understanding of disease spectrum and transform patient care[J].Clin Infect Dis,2013,56(9):1284-1292.

[16]TIAN Y,TANG XP,LI H.Pulmonary aspergillosis in patients with severe hepatitis:it's clinical features and treatments[J].Chin J Hepatol,2007,15(9):697-698.(in Chinese)田沂,唐晓鹏,李慧.重型肝炎合并肺曲霉感染的临床特点与治疗[J].中华肝脏病杂志,2007,15(9):697-698.

[17]SALIBA F,DELVART V,ICHAP,Fungal infections after liver transplantation:outcomes and risk factors revisited in the MELD era[J].Clin Transplant,2013,27(4):e454-e461.

[18]LUCIGNANO B,RANNO S,LIESENFELD O,et al.Multiplex PCR allows rapid and accurate diagnosis of bloodstream infections in newborns and children with suspected sepsis[J].J Clin Microbiol,2011,49(6):2252-2258.

[19] MYLONAKIS E,CLANCY CJ,OSTROSKY-ZEICHNER L,et al.T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood:a clinical trial[J].Clin Infect Dis,2015,60(6):892-899.

[20]LACROIX C,GICQUEL A,SENDID B,et al.Evaluation of two matrix-assisted laser desorption ionization-time of flight mass spectrometry(MALDI-TOF MS)systems for the identification of Candida species[J].Clin Microbiol Infect,2014,20(2):153-158.

[21]VINIKOOR MJ,ZOGHBY J,COHEN KL,et al.Do all candidemic patients need an ophthalmic examination?[J].Int J Infect Dis,2013,17(3):e146-e148.

[22] SEGAL BH.Aspergillosis[J].N Engl J Med,2009,360(18):1870-1884.

[23]MASCHMEYER G,HAAS A,CORNELY OA.Invasive aspergillosis:epidemiology,diagnosis and management in immunocompromised patients[J].Drugs,2007,67(11):1567-601.

[24]DIMOPOULOS G,PIAGNERELLI M,BERRE J,et al.Disseminated aspergillosis in intensive care unit patients:an autopsy study[J].J Chemother,2003,15(1):71-75.

[25]PFEIFFER CD,FINE JP,SAFDAR N.Diagnosis of invasive aspergillosis using a galactomannan assay:a meta-analysis[J].Clin Infect Dis,2006,42(10):1417-1427.

[26]HE H,DING L,SUN B,et al.Role of galactomannan determinations in bronchoalveolar lavage fluid samples from critically ill patients with chronic obstructive pulmonary disease for the diagnosis of invasive pulmonary aspergillosis:a prospective study[J].Crit Care,2012,16(4):r138.

[27]SLOAN DJ,PARRIS V.Cryptococcal meningitis:epidemiology and therapeutic options[J].Clin Epidemiol,2014,6:169-182.

[28]SINGH N,HUSAIN S,de VERA M,et al.Cryptococcus neoformans infection in patients with cirrhosis,including liver transplant candidates[J].Medicine(Baltimore),2004,83(3):188-192.

[29]KAUFFMAN CA,BERGMAN AG,SEVERANCE PJ,et al.Detection of cryptococcal antigen.Comparison of two latex agglutination tests[J].Am J Clin Pathol,1981,75(1):106-109.

[30]CHERUVATTATH R,BALAN V.Infections in patients with end-stage liver disease[J].J Clin Gastroenterol,2007,41(4):403-411.

[31]THOMAS CF,LIMPER AH.Pneumocystis pneumonia[J].N Engl J Med,2004,350(24):2487-2498.

[32]DELORENZO LJ,HUANG CT,MAGUIRE GP,et al.Roentgenographic patterns of Pneumocystis carinii pneumonia in 104 patients with AIDS[J].Chest,1987,91(3):323-327.

[33]GRUDEN JF,HUANG L,TURNER J,et al.High-resolution CT in the evaluation of clinically suspected Pneumocystis carinii pneumonia in AIDS patients with normal,equivocal,or nonspecific radiographic findings[J].AJR Am J Roentgenol,1997,169(4):967-975.

[34]CHOE PG,KANG YM,KIM G,et al.Diagnostic value of direct fluorescence antibody staining for detecting Pneumocystis jirovecii in expectorated sputum from patients with HIV infection[J].Med Mycol,2014,52(3):326-330.

[35]AVINAO LJ,NAYLOR SM,ROECKER AM.A review of pneumocystis jirovecii pneumonia in the non-HIV-Infected population[J].Ann Pharmacother,2016,pii:1060028016650107.[Epub ahead of print]

[36]KARAGEORGOPOULOS DE,QU JM,KORBILA IP,et al.Accuracy of beta-D-glucan for the diagnosis of Pneumocystis jirovecii pneumonia:a meta-analysis[J].Clin Microbiol Infect,2013,19(1):39-49.

[37]LI M,LIAO WQ.The situation in the treatment of invasive fungal infections[J].Chin J Mycol,2012,7(1):47-51.(in Chinese)李梦,廖万清.侵袭性真菌感染治疗新进展[J].中国真菌学杂志,2012,7(1):47-51.

[38]CORNEY OA,BASSETTI M,CALANDRA T,et al.ESCMID guideline for the diagnosis and management of Candida diseases2012:non-neutropenic adult patients[J].Clin Microbiol Infect,2012,18(Suppl 7):19-37.

[39]REBOLI AC,ROTSTEIN C,PAPPAS PG,et al.Anidulafungin versus fluconazole for invasive candidiasis[J].N Engl J Med,2007,356(24):2472-2482.

[40]PAPPAS PG,KAUFFMAN CA,ANDES DR,et al.Clinical practice guideline for the management of candidiasis:2016 update by the Infectious Diseases Society of America[J].Clin Infect Dis,2016,62(4):e1-e50.

[41] WALSH TJ,ANAISSIE EJ,DENNING DW,et al.Treatment of aspergillosis:clinical practice guidelines of the Infectious Diseases Society of America[J].Clin Infect Dis,2008,46(3):327-360.

[42] VERMEULEN E,MAERTENS J,de BEL A,et al.Nationwide surveillance of azole resistance in aspergillus diseases[J].Antimicrob Agents Chemother,2015,59(8):4569-4576.

[43]PERFET JR,DISMUKES WE,DROMER F,et al.Clinical practice guidelines for the management of cryptococcal disease:2010 update by the infectious diseases society of america[J].Clin Infect Dis,2010,50(3):291-322.

[44]PAPPAS PG.Cryptococcal infections in non-HIV-infected patients[J].Trans Am Clin Climatol Assoc,2013,124:61-79.

[45] KAUFFMAN CA,PAPPAS PG,SOBEL J,et al.Essentials of clinical mycology[M].New York:Springer,2011.

[46]HELWEG-LARSEN J,BENFIELD T,ATZORI C,et al.Clinical efficacy of first-and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia:a tri-centre cohort study[J].J Antimicrob Chemother,2009,64(6):1282-1890.

施引文献

资源附件(0)

访问统计